Afficher la notice abrégée

Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease

dc.rights.licenseopenen_US
dc.contributor.authorDRUBE, J.
dc.contributor.authorWAN, M.
dc.contributor.authorBONTHUIS, M.
dc.contributor.authorWUHL, E.
dc.contributor.authorBACCHETTA, J.
dc.contributor.authorSANTOS, F.
dc.contributor.authorGRENDA, R.
dc.contributor.authorEDEFONTI, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHARAMBAT, Jerome
IDREF: 110567358
dc.contributor.authorSHROFF, R.
dc.contributor.authorTONSHOFF, B.
dc.contributor.authorHAFFNER, D.
dc.date.accessioned2020-06-05T13:46:20Z
dc.date.available2020-06-05T13:46:20Z
dc.date.issued2019-09
dc.identifier.issn1759-507X (Electronic) 1759-5061 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7791
dc.description.abstractEnAchieving normal growth is one of the most challenging problems in the management of children with chronic kidney disease (CKD). Treatment with recombinant human growth hormone (GH) promotes longitudinal growth and likely enables children with CKD and short stature to reach normal adult height. Here, members of the European Society for Paediatric Nephrology (ESPN) CKD-Mineral and Bone Disorder (MBD), Dialysis and Transplantation working groups present clinical practice recommendations for the use of GH in children with CKD on dialysis and after renal transplantation. These recommendations have been developed with input from an external advisory group of paediatric endocrinologists, paediatric nephrologists and patient representatives. We recommend that children with stage 3-5 CKD or on dialysis should be candidates for GH therapy if they have persistent growth failure, defined as a height below the third percentile for age and sex and a height velocity below the twenty-fifth percentile, once other potentially treatable risk factors for growth failure have been adequately addressed and provided the child has growth potential. In children who have received a kidney transplant and fulfil the above growth criteria, we recommend initiation of GH therapy 1 year after transplantation if spontaneous catch-up growth does not occur and steroid-free immunosuppression is not a feasible option. GH should be given at dosages of 0.045-0.05 mg/kg per day by daily subcutaneous injections until the patient has reached their final height or until renal transplantation. In addition to providing treatment recommendations, a cost-effectiveness analysis is provided that might help guide decision-making.
dc.language.isoENen_US
dc.rightsAttribution 4.0 International (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.enLEHA
dc.title.enClinical practice recommendations for growth hormone treatment in children with chronic kidney disease
dc.title.alternativeNat Rev Nephrolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41581-019-0161-4en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31197263en_US
bordeaux.journalNature Reviews Nephrologyen_US
bordeaux.page577-589en_US
bordeaux.volume15en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue9en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03209337
hal.version1
hal.date.transferred2021-04-27T08:36:11Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nature%20Reviews%20Nephrology&rft.date=2019-09&rft.volume=15&rft.issue=9&rft.spage=577-589&rft.epage=577-589&rft.eissn=1759-507X%20(Electronic)%201759-5061%20(Linking)&rft.issn=1759-507X%20(Electronic)%201759-5061%20(Linking)&rft.au=DRUBE,%20J.&WAN,%20M.&BONTHUIS,%20M.&WUHL,%20E.&BACCHETTA,%20J.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
2019_BPH_Drube.pdf
Taille:
1.027Mo
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée